Thomson Reuters Unveils Nominees For The Top BioPharma Deals Of The Year
PHILADELPHIA, May 3, 2016 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters, the world's leader in intelligent information for businesses and professionals, announced the nominees for the Allicense 2016 Breakthrough Awards, honoring the leading deals of 2015 in Biopharmaceutical Licensing and in Mergers and Acquisitions (M&A).
The awardsto be determined by public votewill be presented on Wednesday, June 8 at Allicense in San Francisco, California. Allicense is an annual event that brings together the industry's leading minds from the Pharmaceutical, Biotech and Financial communities to tackle today's most relevant issues and shape the future of dealmaking. Allicense is the only event where 200+ qualified dealmakers focus exclusively on key issues facing the industry.
This year's nominees include five contenders in each of the two categories, and were determined using Thomson Reuters Recap, a deal maker's solution that offers rapid insight and reports for biopharmaceutical key business development and licensing decisions.
Members of the biopharmaceutical community are invited to vote for the top breakthrough deals in each category until 3:45 PM on Wednesday, June 8.
The nominees are:
LICENSING:
Licensee & Licenser | Subject |
Vertex Pharmaceuticals and CRISPR Therapeutics | CRISPR-Cas9 gene editing technology to discover and develop new treatment for genetic diseases |
Gilead Sciences and Galapagos | Galapagos' filgotinib targeting rheumatoid arthritis and inflammatory disease |
Pfizer and Heptares Therapeutics | Develop novel drugs targeting GPCR against therapeutic indications |
AstraZeneca/Medlmmune and Innate Pharma | IPH2201, an anti-NKG2A humanized IgG4 antibody in immuno-oncology |
Sanofi/Genzyme and Voyager Therapeutics | Adeno-associated viral (AAV) gene therapies for severe CNS disorders |
MERGERS & ACQUISITIONS:
Buyer | Seller |
Alexion Pharmaceuticals | Synageva BioPharma |
AstraZeneca | Acerta Pharma |
Bristol-Myers Squibb | Cardioxyl Pharmaceuticals |
Roche Pharma | Foundation Medicine |
Celgene | Quanticel Pharmaceuticals |
"The role of M&A, licensing and partnering continues to be a prominent mechanism to address the many challenges facing the global pharmaceutical industry," said Richard Harrison, Chief Scientific Officer, Intellectual Property & Science, Thomson Reuters. "The nominees for our Allicense 2016 Breakthrough Awards represent the top deal-makers of this landmark year. We look forward to seeing who the biopharma community decides has made the biggest impact on the industry this year."
Visit Allicense.com, to cast your vote, register for the event, and learn more details behind the nominations.
Thomson Reuters
Thomson Reuters is the world's leading source of news and information for professional markets. Our customers rely on us to deliver the intelligence, technology and expertise they need to find trusted answers. The business has operated in more than 100 countries for more than 100 years. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges (symbol: TRI). For more information, visit www.thomsonreuters.com.
CONTACTS | |
Jennifer Figueroa +1.203.824.6261 Jennifer.figueroa@thomsonreuters.com
Pamela Lim +65 6870 3212
| |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/thomson-reuters-unveils-nominees-for-the-top-biopharma-deals-of-the-year-300261875.html
SOURCE Thomson Reuters
